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Abstract To identify the most promising vaccine candidates for combinatorial strategies, we
compared five SIV vaccine platforms including recombinant canary pox virus ALVAC,
replication-competent adenovirus type 5 host range mutant RepAd, DNA, modified vaccinialood mononuclear cells; TNF-α, tumor necrosis factor α; IFN-γ, interferon γ; IM, intramuscular; IN,
IR, intrarectal; ADCC, antibody-dependent cell-mediated cytotoxicity; ADCVI, antibody-dependent
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Ankara (MVA), peptides and protein in distinct combinations. Three regimens used viral vectors
(prime or boost) and two regimens used plasmid DNA. Analysis at necropsy showed that the
DNA-based vaccine regimens elicited significantly higher cellular responses against Gag and Env
than any of the other vaccine platforms. The T cell responses induced by most vaccine regimens
disseminated systemically into secondary lymphoid tissues (lymph nodes, spleen) and effector
anatomical sites (including liver, vaginal tissue), indicative of their role in viral containment at
the portal of entry. The cellular and reported humoral immune response data suggest that
combination of DNA and viral vectors elicits a balanced immunity with strong and durable
responses able to disseminate into relevant mucosal sites.
Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
To date, four clinical efficacy trials against HIV have been
conducted including: (i) gp120 protein vaccine (VaxGen) [1–4];
(ii) recombinant Ad5 (STEP) [5–7]; (iii) DNA prime-recombinant
Ad5 boost (HVTN 505) [8]; (iv) combination of recombinant
Canarypox ALVAC®-HIV (vCP1521; containing Gag, PR and
Env) with gp120 Env protein (AIDSVAX® B/E) (referred to as
RV144, conducted in Thailand) [9]. Only the RV144 trial
showed modest statistically significant protection from infec-
tion [9]. This trial revealed a critical role of humoral responses
in preventing infection [10–14]. The humoral immune re-
sponse waned rapidly after vaccination, indicating the need
for vaccine regimens that provided longer-lasting immunity. In
addition, no difference in the levels of viremia were found
between infected vaccinees and unvaccinated controls,
indicating suboptimal cellular immune responses induced by
this vaccine protocol. Thus, there is a need to develop a
vaccine regimen against HIV that is able to provide effective
humoral responses to prevent virus acquisition as well as
potent cytotoxic effector memory T cell responses able to
contain infection. Importantly, it is critical that humoral and
cellular responses disseminate efficiently to mucosal sites
(rectum, vagina), since these are portals of entry for HIV
infection.
The five sections of the National Cancer Institute's
Vaccine Branch have been studying distinct vaccine
regimens, which have shown some degree of protection
from virus acquisition and/or significant control of peak
and/or chronic viremia such as: (i) ALVAC/Env vaccine
using a recombinant canary pox virus (ALVAC) vector
in combination with an Env protein boost delivered
via the intramuscular route (IM) [15–19] (Vaccari M.
et. al., manuscript in preparation); (ii) RepAd/Env vaccine
consisting of mucosal priming by replication-competent
adenovirus type 5 host range mutant recombinants (RepAd)
followed by an IM-delivered Env protein boost [20–25];
(iii) DNA vaccine delivered via the IM route followed
by electroporation (EP) [26–33]; (iv) DNA&Env vaccine
consisting of DNA and Env protein co-immunization
delivered as in (iii) [31,32]; and (v) IL-15-adjuvanted
viral-specific peptides given together with a TLR agonist
delivered intrarectally in combination with recombinant
modified vaccinia Ankara (MVA) vectors and Env protein
[34–37]. In a comparative study, we tested these five vaccine
regimens side-by-side in rhesus macaques and we have
recently reported on our comparison and characterizationof the humoral responses induced by these platforms [38].
We found that the ALVAC/Env, RepAd/Env and DNA&Env
regimens induced robust systemic binding antibodies
with neutralizing activity and able to mediate antibody-
dependent cellular cytotoxicity (ADCC) and opsonization.
Mucosal IgA and IgG responses were readily detected in
animals vaccinated with ALVAC/Env, RepAd/Env, DNA&Env
and DNA at necropsy, but the RepAd/Env regimen induced the
earliest mucosal SIV-specific IgA responses.
Several lines of evidence support the importance of
cellular responses for the control of viral propagation
in HIV-infected individuals. Some studies reported an
association between CTL responses against HIV proteins
and control of viremia [39–46]; other studies demonstrated
that high avidity CTLs targeting strictly conserved viral
regions are preferentially found in HIV-infected control-
lers and long-term non-progressors [47,48]. Similarly, a
correlation between vaccine-induced cellular responses
and improved control of viremia has also been described
using the SIV/rhesus macaque model [22,27,32,49–64].
Among the vaccine platforms studied in our branch, a
correlation between vaccine-induced cell-mediated responses
and reduction of viremia was found in DNA immunized animals
challenged with SIVmac251 [27,62], in DNA and DNA&Env
immunized macaques challenged with SIVsmE660 [32], in
DNA-ALVAC immunized animals challenged with SIVmac251
[19], in RepAd/Env vaccinated animals challenged with
SIVmac251 [22,63,64] and upon intrarectal peptide and MVA
vaccine vaccination challenged with SIVmac251 or SHIVKu2
[34–37]. The referred vaccination regimens also induced
humoral responses against Env, therefore it was unclear
whether vaccine-induced T cell responses only, in the absence
of humoral responses, were sufficient to mediate control
of viremia. However, several studies in macaques un-
equivocally demonstrated the efficacy of T cell responses
in controlling highly pathogenic SIVmac: (i) animals
vaccinated with recombinant CMV expressing SIV antigens
controlled viremia to undetectable level in the presence
of vaccine-induced CTL responses and absolute absence
of anti-SIV humoral responses [65–67]; (ii) macaques
vaccinated with immunogens lacking an Env component
were able to significantly control viremia [68–72]. In the
present study, we report a comparison of systemic cellular
immune responses induced by the different vaccine
platforms being explored in our Vaccine Branch, which
may provide suggestions for combinations that further
optimize vaccine regimens.
Figure 1 Schematic representation of the vaccination regimens used in the study, an adaptation from Vargas-Inchaustegui et al. [38].
The five immunization regimens are detailed and the times of vaccination are given in weeks. The number of animals per group and the
route of vaccine administration (IM: intramuscular; IN + O: intranasal and orally; IT: intratracheal; IR: intrarectal) are shown to the left. The
key vaccine components are shown in boxes, and the proteins and adjuvants are highlighted in gray.
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2.1. Vaccination regimensThe Indian rhesusmacaques included in the study were housed
and maintained at the Advanced BioScience Laboratories, Inc.
(ABL, Rockville, MD) following the standards of the American
Association for Accreditation of Laboratory Animal Care and
the Guide for the Care and Use of Laboratory Animals of the
NIH. The ABL Animal Care and Use Committee approved the
protocols prior to implementation. All macaques enrolled in
the study (N = 22) were positive for the MamuA*01 MHC class I
allele. The animals were negative for infection by SIV, simian
T-cell leukemia virus-type 1 and simian type D retrovirus.
The animals were immunized with five different vaccine
regimens (ALVAC/Env, RepAd/Env, DNA&Env, DNA, and
Peptide/MVA/Env) as previously described [38]; the details
for each protocol are summarized in Fig. 1. Briefly, the ALVAC/Env protocol (N = 6) consisted of 4 vaccinations (weeks 0, 4,
12, 24) with SIV gag/pro/env ALVAC vector (1 × 108 pfu
VCP2432) via the intramuscular (IM) route including 2 vaccina-
tions (weeks 12, 24) with 400 μg of SIV gp120 protein
adjuvanted in Alum (200 μg of SIVM766.4 gp120 and 200 μg of
SIVCG7V gp120).
The RepAd/Env protocol (N = 4) consisted of Ad5hr-
SIVsmH4env/rev and Ad5hr-SIV239gag (5 × 108 pfu) delivered
intranasally (IN) and orally (O) at week 0, and intratracheally
(IT) at week 12, followed by two protein boosts (100 μg
of M766 gp120 adjuvanted in 10 μg of EM-005; Infectious
Disease Research Institute, Seattle, WA) at weeks 24 and 36.
The DNA (N = 4) and DNA&Env (N = 4) protocols consisted
of the same plasmid DNA mixture (3 mg of Env DNA, 1 mg of
Gag DNA and 0.2 mg of macaque IL-12 DNA) administered 4
times (weeks 0, 9, 17 and 25) via the IM route followed by in
vivo electroporation (IM/EP; Inovio Pharmaceuticals, Inc.,
Blue Bell, PA). The DNA&Env co-immunization regimen
included administration of 100 μg Env protein (M766-like
Figure 2 SIV-specific cellular immune responses in PBMC at the time of necropsy. PBMCs from blood collected 2 weeks after the
last immunization (4 weeks for macaques of the ALVAC/Env group) were stimulated with peptides covering (A–C) Gag or (D–E) Env.
The frequency of SIV-specific cells producing IFN-γ, TNF-α or both (cytokine+) were measured by flow cytometry. Total CD3+ T cell
responses (A, D), CD4+ T cell responses (B, E) and CD8+ T cell responses (C, F) are shown. The order of the animals within each vaccine
group were ALVAC/Env: P464; P836; P841; P851; P862; P863; RepAd/Env: P445, P450, P451, P576; DNA&Env: P181; P447; P515; P520;
DNA: P516; P517; P518; P519; Pep/MVA/Env: R216; R217; R452; R451.
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delivered by IM route into the same muscle following the
DNA electroporation.
The Peptide/MVA/Env protocol (N = 4) consisted of a
mixture of SIV/HIV peptides (13 peptides including epitopes
of HIV Env and Tat, and SIV Gag, Pol, Rev, Tat, and Vif at
0.5 mg/peptide) delivered intrarectally (IR) at weeks 0, 3
and 6 together with a cocktail containing IL-15 (300 μg), the
TLR agonists MALP2 (10 μg), polyI:C (1 mg) and CpG (500 μg)
per dose as adjuvant. The boost consisted of recombinant
MVA vectors (dose of 5 × 108 pfu MVA-SIVmac239 env, gag, and
pol, and MVA-SIVmac239 tat, nef, and rev) together with the
above described adjuvant cocktail, and 100 μg M766 gp120
adjuvanted with mutant Escherichia coli labile toxin R192G
(mLT, 50 μg/dose, a kind gift of J. Clements, Tulane
University, New Orleans, LA) administered IR at weeks 10
and 13. This vaccine was designed to elicit mostly colorectal
mucosal immunity.
The proteins used in these vaccine regimens included
HEK293 cell produced M766 gp120 (RepAd/Env; Peptide/
MVA/Env) and the trimeric gp140 proteins (DNA&Env)purified from cells grown in serum-free media in a Hollow
Fiber bioreactor; CHO cell produced gD-tagged M766 and
CG7V proteins (ALVAC/Env).2.2. Sample collection and tissue processing
Tissues collected at necropsy (axillary and inguinal lymph
nodes, spleen, liver and vagina and rectum) were placed in
RPMI 1640 medium and kept on ice until processing. PBMCs
were isolated from blood samples drawn in EDTA-tubes by
Ficoll-Histopaque (Histopaque, Sigma, St. Louis, MO) gradi-
ent centrifugation. For spleen and lymph nodes lymphocyte
purification, the tissues were gently squeezed through a
100-μm cell strainer (Thomas Scientific) and washed in
PBS supplemented with 0.2% heat-inactivated human AB+
serum. The cells were resuspended in RPMI 1640 containing
10% FCS and counted using Acridine Orange (Molecular
Probes) and ethidium bromide (Fisher Scientific) dye to
assess cell viability. To isolate lymphocytes from liver and
vaginal biopsies, the tissues were minced and incubated in
Figure 3 Gating strategy for the flow cytometric analysis of Gag CM9-specific tetramer+ CD8+ T cell responses. Single CD4+ and CD8+ T
lymphocyte subsets were determined from the live CD3+ T cell population. Central memory (CM) and effector memory (EM) subsets were
defined within the CD8+ T cells by staining with CD95 and CD28. Gag CM9 Tetramer positive cells are shown from the CD8+ CM and EM T cell
populations. Numbers within the gates represent the percentage of tetramer positive cells.
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30 U/ml DNase (Roche) for 1.5 h at 37 °C under continuous
shaking. Clumps and tissue debris were removed by
centrifugation at 800 rpm for 1 min and the fluids containing
single cells were collected, transferred into a new tube and
washed with PBS supplemented with 0.2% human serum.
2.3. Antigen-specific cell-mediated responses
Analysis of vaccine-induced cellular responses upon peptide
stimulation was performed in cryopreserved PBMC. After
thawing, macaque PBMCs were cultured in RPMI medium
supplemented with 10% fetal bovine serum at a concentra-
tion of 2 × 106 cells/ml. PBMCs were stimulated overnight
with peptide pools (final concentration of 1 μg/ml for each
peptide) in the presence of monensin (BD Pharmingen, San
Diego, CA). The peptide pools consisted of 15-mers
overlapping by 11 AA covering p39gag and gp160 Env of
SIVmac239. Antigen-specific T cells were monitored by a
protocol that combines cell surface phenotyping and
intracellular cytokine staining followed by flow cytometry.
The cells were stained with the following cocktail of cell
surface antibodies: CD3-APCCy7 (clone SP34-2), CD4-V500
(clone L200), CD95-FITC (clone DX2) (BD Pharmingen),CD8-Alexa Fluor-405 (clone 3B5, Invitrogen, Carlsbad, CA),
and CD28-PerCP Cy5.5 (clone CD28.2, BioLegend, San Diego,
CA). After cell permeabilization with Cytofix/Cytoperm (BD
Biosciences), intracellular staining was performed using
IFN-γ-PE Cy7 (clone B27, BD Pharmingen), TNF-α-AF700
(clone Mab11, BD Pharmingen) and Granzyme B-PE antibod-
ies (clone GB12, Invitrogen). PBMCs cultured in medium
without peptide pools or stimulated with phorbol myristate
acetate (PMA) and calcium ionophore (Sigma, St. Louis, MO)
were used as negative and positive control, respectively.
At least 105 T cells from each sample were acquired on an
LSR II flow cytometer (BD Biosciences, San Jose, CA) and the
data were analyzed using FlowJo software (Tree Star, Inc.,
Ashland, OR). Samples were considered positive if the
frequency of the cytokine positive T cells in the peptide-
stimulated samples was more than 2-fold higher than the
frequency obtained in the unstimulated medium only control
sample. Statistical analysis was performed using ANOVA
(Graphpad Prism version 6).
2.4. Tetramer staining
Lymphocytes recovered from the different tissues collected
at necropsy were washed with PBS supplemented with 0.2%
Figure 4 Gag CM9 tetramer responses in CD8+ T lymphocytes at necropsy. The frequency of Gag-specific CM9+ CD8+ T lymphocytes
elicited by the different vaccine regimenswasmeasured in PBMC by combined tetramer staining and cell surface phenotyping formemory T
cells subsets followed by flow cytometry. The plots show the percentage of CM9+ CD8+ T lymphocytes among (A) total CD8+ T cells,
(B) effectormemory (CD95+CD28−) and (C) centralmemory (CD95+CD28+) CD8+ T lymphocytes. (D) The ratio of CM/EM among the tetramer+
CD8+ T cells is shown.
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for 10 min. The cells were resuspended in 5 μl of CM9-PE
tetramer (MamuA*01-CTPYDINQM, Beckman Coulter) and,
after 5 min, a cocktail containing CD3-APCCy7 (clone SP34-2;
BD Pharmingen), CD4-V500 (clone L200; BD Pharmingen),
CD95-FITC (clone DX2; BD Pharmingen) CD8-Alexa Fluor-405
(clone MHCD0826, Invitrogen) CD28-PerCP Cy5.5 (clone
CD28.2, BioLegend, San Diego, CA), CD45RA-AF700 (clone
F8-11-13, ABD Serotec, UK) and CCR7-APC (clone 150503,
R&D) antibodies was added to the samples and furtherincubated for 30 min at room temperature. After the
incubation, the cells were washed with PBS and acquired in a
LSR II flow cytometer (BD Biosciences, San Jose, CA). Tetramer
staining in PBMC was performed using cryopreserved samples
collected at necropsy. After thawing, the cells were counted
and 106 PBMCs were stained with the Aqua Live/Dead
(Invitrogen) viability dye. After washing, the cells were
exposed to the CM9-PE tetramer, and after incubation a
cocktail containing CD3-APC, CD4-PerCP Cy5.5, CD8-APCCy7,
CD28-FITC, CD95-PE Cy7 (BD Pharmingen) was added to the
97Cellular immunity induced by different vaccine regimenscells. After 20 min of incubation, the cells were washed,
fixed in 1% Paraformaldehyde and acquired in the flow
cytometer. For all the tetramer stained samples, at least
5 × 104 CD8+ T cells were acquired from each tube and the
data were analyzed using FlowJo software (Tree Star,Figure 5 Flow cytometric analysis of Gag CM9-specific responses in
group. Flow plots show the frequency (numbers given within the gate)
(axillary, inguinal), spleen, liver, and vaginal samples from a represen
absence of samples from the vagina because all animals in the RepAd/Inc.). Samples were considered positive if the frequency of
the Gag CM9 tetramer positive CD8+ T cells was more than
2-fold higher than the frequency obtained in samples
collected before vaccination or in MamuA*01 negative
samples.different tissues at necropsy of an exemplary animal from each
of CM9 tetramer+ CD8+ T lymphocytes among PBMCs, lymph nodes
tative macaque from each vaccine regimen. Asterisk denotes the
Env group were males.
Figure 6 Gag CM9 tetramer responses analyzed in different tissues from all vaccine groups. The presence of Gag-specific CM9+ CD8+
T lymphocytes was detected by flow cytometry after tetramer staining of lymphocytes recovered from (A) lymph nodes, (B) spleen,
(C) liver, and (D) vagina. The plots show the frequency of CM9+ CD8+ T lymphocytes as a percentage of the parental total CD8+ T
lymphocyte population.
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3.1. Comparison of the five vaccine platforms tested
in macaques
Macaques were vaccinated with regimens expressing SIV
antigen as outlined in Fig. 1. The ALVAC/Env regimen
consisted of four vaccinations with recombinant ALVAC
expressing SIV gag/pol and env, including two SIV Env
protein boosts. The RepAd/Env regimen included two
vaccinations with recombinant replicating Adenovirus ex-
pressing gag, env and rev followed by two boosts with SIV
Env protein. The DNA-based protocols included four vacci-
nations with a mixture of DNAs expressing gag and env,
whereas the DNA&Env co-immunization regimen included
codelivery of Env protein in the same muscle following
the DNA electroporation. The Peptide/MVA/Env regimen
consisted of three vaccinations with a mixture of HIV and SIV
peptides covering helper and cytotoxic T cell epitopes,
followed by two boosts with recombinant MVA expressing
different SIV genes together with SIV Env protein, all
delivered intrarectally to induce colorectal mucosal immu-
nity [34–36]. Of note the vaccines were delivered via
different routes such as intramuscular (IM) for ALVAC/Env,
DNA&Env and DNA vaccines, intrarectal route (IR) for the
Peptide/MVA/Env vaccine and several mucosal routes
including oral (O), intranasal (IN) and intratracheal (IT) forthe RepAd regimen. The Env protein was formulated with
different adjuvants including Alum (ALVAC/Env), EM-005
(RepAd/Env; DNA&Env) and mLT (Peptide/Env). We previ-
ously reported on the humoral responses in these macaques
[38]. This report focuses primarily on the cellular immune
responses monitored in peripheral blood and in different
tissues at necropsy at 2 to 4 weeks after the last
vaccination.
3.2. Peptide-specific cellular immune responses in
blood at necropsy
For the measurement of SIV-specific cellular immune
responses at the time of necropsy, peptide-stimulated
PBMC were analyzed by intracellular staining with antibodies
against IFN-γ and TNF-α and the frequency of both Gag- and
Env-specific cytokine+ T cells was determined by flow
cytometry (Fig. 2). All animals immunized with plasmid
DNA (DNA&Env and DNA only groups) as well as 2 of the 4
animals from the RepAd/Env group showed Gag-specific
cytokine+ T cell responses (Fig. 2A). In contrast, Gag-specific
T cells were absent in the animals immunized with either the
ALVAC/Env or Pep/Env regimens. The highest level of Gag
responses was found in the DNA only group (range 0.4–0.7%
of the total T cells), followed by the DNA&Env group (range
0.01–0.5%) and the RepAd/Env group (range 0.01 and 0.04%
of the 2 responders). Comparison of these three groups
Figure 7 Antigen-specific T cells in PBMC measured during the course of vaccination. PBMCs from blood collected 2 weeks after the
3rd immunization for all vaccine groups except at 2 weeks after the 2nd vaccination for the ALVAC/Env group were stimulated with
peptides covering (A–C) Gag and (D–F) Env. The frequency of SIV-specific cells producing IFN-γ, TNF-α or both (cytokine+) were
measured by flow cytometry. Total (A, D), CD4+ (B, E) and CD8+ (C, F) T cell responses are shown. Samples from the Pep/Env group
were not included in the analysis. The order of the animals within the vaccine groups was kept the same as described in Fig. 2.
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DNA only group compared to RepAd/Env and no difference
between DNA and DNA&Env group using ANOVA. All positive
animals, except one in the RepAd/Env group, developed
anti-Gag responses characterized by the production of both
IFN-γ and TNF-α, although we noted that the responses
were clearly dominated by the production of IFN-γ. The
Gag-specific responses were mediated by both CD4+ (Fig. 2B)
and CD8+ T lymphocytes (Fig. 2C), although the CD8+ T
responses were higher for the majority of the animals
(Fig. 2C, note different scale).
Next, PBMCs were analyzed for the presence of Env-
specific cytokine+ T cell responses. Only the vaccine regimens
including plasmid DNA (DNA, DNA&Env) and RepAd/Env (one of
the animals in this group could not be evaluated due to the
very low number of cells in the sample) showed Env-specific
cellular responses at necropsy (Fig. 2D). Animals enrolled in
the DNA only vaccine group had the highest anti-Env cellular
responses (range between 0.3–3.6% of the total T cells),
followed by the DNA&Env regimen (range 0.13–1.7%), and the
RepAd/Env protocol (range 0.03–0.09%) (Fig. 2D), which issimilar to the responses observed for Gag (see above, Fig. 2A).
Similar to the observation of the Gag responses, we found
significantly higher level of Env-specific responses (Fig. 2D) in
the DNA only group compared to RepAd/Env and no difference
between DNA and DNA&Env group using ANOVA. The responses
in the two groups that included plasmid DNA were preferen-
tially mediated by CD8+ T lymphocytes (Fig. 2F), whereas CD4+
T cells dominated the anti-Env cellular responses elicited by
the RepAd/Env regimen (Fig. 2E, note the different scale).
The Env-specific T cells produced primarily IFN-γ, although
one animal from the DNA only regimen showed a higher
frequency of TNF-α secreting cells CD4+ T cells (Fig. 2E).
Together, we found distinct efficacy and magnitude by the
different vaccine regimens in inducing SIV-specific cellular T
cell responses. We cannot rule out that the time point
selected for the ALVAC/Env group may have been suboptimal,
since this group showed positive responses at 2 weeks after
the 3rd vaccination (see below Fig. 7). Thus, vaccine platforms
such as plasmid DNA, DNA&Env co-immunization and RepAd/
Env were the most potent in eliciting Gag- and Env-specific
cellular immune responses in the blood at necropsy.
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at necropsy
Since all macaques enrolled in this study expressed the
mamuA*01 MHC class I allele, we also analyzed the
Gag181–189 (CM9) tetramer responses in PBMC, because this
epitope was present in all the vaccine platforms. The
sequential gating strategy used for the analysis of tetramer
responses in PBMC is shown in Fig. 3. Briefly, the main
lymphocyte population was identified by the scatter prop-
erties within single cells. After excluding dead cells, T
lymphocytes were gated based on CD3 expression, and CD4+
and CD8+ T cells were identified within CD3+ lymphocytes.
Central memory (CM) and effector memory (EM) T cells were
defined based on the expression of CD95 and CD28, and,
finally, the percentage of Gag CM9 tetramer positive cells
was determined within these lymphocyte populations were
shown for a representative DNA vaccinated animal.
Analysis of all the animals showed (Fig. 4A) that
vaccination protocols including DNA, especially the DNA
only group, had the highest CM9 tetramer responses among
the CD8+ T cells (range 1.3% to 4% for the DNA/Protein and
1.6% to 18% for the DNA only group), Interestingly, although
two of the animals from the RepAd/Env group were negative
for peptide-induced Gag responses (Fig. 2A), all the animals
within this group showed positive CM9 tetramer responses
(range from 0.1 to 1.1% of total CD8+ T cells) (Fig. 4A).
Similarly, one animal in the ALVAC/Env group was also found
positive for CM9-specific CD8+ T cell responses by tetramer
staining (0.8% of total CD8 T cells) (Fig. 4A), although this
animal was negative upon peptide stimulation (Fig. 2A). No
tetramer positive CD8+ T cells were found in PBMC of any of
the animals vaccinated with the Pep/Env regimen.
Since the CM9 tetramer staining was performed in
combination with antibodies against CD28 and CD95, the
memory phenotype of this CD8+ T cell population was further
analyzed (Figs. 4B and C). The DNA-based vaccines induced
preferentially effector memory EM (CD95+ CD28−) cells
(Fig. 4B). The responses showed ranges of 1.9% to 5.7% for
the DNA&Env; 1.7% to 23.2% for the DNA only, and 0.17% to
1% in the RepAd/Env. A substantial fraction of the CM9+ CD8+
T cells was also found among the CM (CD95+CD28+)
subpopulation (0.2% to 2.5% in the DNA&Env; 1.6% to 14.9%
in the DNA only, and 0.2% to 2% in the RepAd/Env group)
(Fig. 4C). Similarly, the only macaque with detectable CM9
responses in the ALVAC/Env group had both EM and CM CM9+Table 1 Macaques with positive cellular immune responses at ne
Tissue Assay Number of positive animals p
ALVAC/Env
(N = 6)
RepAd/En
(N = 4)
PBMC Gag peptides 0 2
Env peptides 0 3
CM9 1 4
LN CM9 2 4
Spleen CM9 2 4
Liver CM9 4 4
Vagina CM9 1 of 3 ND b
a Designed to induce primarily colorectal immunity.
b ND, not done, only male macaques in this group.CD8+ T cells (0.57% and 1.7%, respectively), with a higher
fraction of CM memory CD8+ T lymphocytes. Together, these
data showed that inclusion of DNA in the vaccine resulted in
the highest CM9 tetramer responses, including both EM and
CM CD8+ T cells. Interestingly, we noted that although
animals in the RepAd/Env group had overall lower responses,
they showed the most balanced distribution of CM9 tetramer
positive cells as judged by the higher CM/EM ratio found
among the tetramer positive CD8+ T lymphocytes (Fig. 4D).
In contrast, the DNA-based vaccines induced responses that
favored EM phenotype. These data demonstrate the vaccine
regimens compared in this study induce cellular responses
with distinct efficacy, magnitude, and characteristics.3.4. Tissue distribution of antigen-specific
CD8+ T cells
Samples from different organs were collected at necropsy
and the systemic dissemination of vaccine-induced cellular
responses was analyzed by Gag CM9 tetramer staining.
Primary flow plot data from one representative animal
from each vaccination group are shown in Fig. 5, including
all the tissues that were analyzed by Gag CM9 tetramer
staining: PBMC (A, see also Fig. 4), lymphoid tissue (lymph
nodes; B), spleen (C), liver (D) and mucosal sites (vagina)
(E). Note that all the animals included in the RepAd/Env
regimen were males and, therefore, dissemination of
cellular responses into the genital tract could not be
addressed. No rectal samples were available due to a
technical error, making it impossible to assess responses
induced in this mucosal site by the different vaccine
protocols.
The analysis of the different tissues from all the animals is
shown in Fig. 6. Table 1 compares the numbers of positive
responders among the different groups from the data shown
in Figs. 4 and 6. All vaccine platforms tested, except the
Pep/Env regimen, showed the presence of Gag CM9-specific
responses in different tissues, albeit we noted a great
difference in the efficacy of inducing cellular immune
responses among the groups. CM9-specific T cells present
in lymph nodes reflect the dissemination of the cellular
responses into secondary lymphoid organs (Fig. 6A). Com-
pared to the other tissues (Fig. 6B–D, note different scale),
the frequency of CM9-specific CD8+ T cells was lowest in
lymph nodes. This finding is expected because typicallycropsy.
er vaccine group
v DNA&Env
(N = 4)
DNA
(N = 4)
Peptide/MVA/Env a
(N = 4)
4 4 0
4 4 0
4 4 0
4 4 0
4 4 0
4 4 0
2 of 2 2 of 2 0 of 2
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The frequency of CM9-specific CD8+ T cells ranged from
0.03–0.38% for the DNA&Env group; 0.31% to 2% for the DNA
only group; 0.05% to 0.97% for the RepAd/Env, and 0.08% to
0.37% for the two positive animals in the ALVAC/Env group.
Interestingly, one animal from the ALVAC/Env group lacking
both detectable Gag peptide-induced responses and Gag
CM9-specific CD8+ T cells in PBMC (Figs. 2A and 4A) showed
Gag CM9-specific responses in the lymph nodes (Fig. 6A).
Lymphocytes recovered from the spleen represent a
mixture of secondary lymphoid tissue and peripheral blood,
and therefore the percentage of Gag CM9-specific CD8+ T
cells is expected to be higher than in lymph nodes (Fig. 6B).
The range of CM9-specific CD8+ T cells measured in these
samples were 0.5% to 1.8% for DNA&Env group; 1.1% to 6.7%
for DNA only; 0.05% to 0.5% for RepAd/Env, and 0.06% to
2% for ALVAC/Env group. Similar to the results obtained
in lymph nodes, all macaques in the DNA, DNA&Env, and
RepAd/Env groups and two of the animals in the ALVAC/Env
group showed positive tetramer responses in the spleen.
Lymphocytes recovered from the liver were analyzed
to monitor dissemination of cellular responses into a
non-lymphoid effector site (Fig. 6C). The vaccine regimens
including DNA induced the highest CM9 tetramer responses
(range 1.4% to 2.7% for DNA&Env group and 2.4% to 11.7% for
the DNA only group). All the animals in the RepAd/Env group
had Gag CM9+ T cells in this effector site (range 0.06–0.55%),
while four of the six macaques from the ALVAC/Env group
showed tetramer responses (0.03% to 2.2%), albeit the
responses in three of the four responders were very low.
Vaginal samples were collected to address the dissemi-
nation of vaccine-induced cellular responses to mucosal sites
(Fig. 6D). This site is highly relevant because HIV infection is
mainly transmitted at mucosal sites including the genital
tract. With the exception of RepAd/Env group, half of the
animals (2–3 animals) in each group were females. Four of
the macaques, which received a DNA-based vaccine, showed
CM9-specific CD8+ T cells with a frequency of 1.24% and 4% in
the DNA&Env group, and 1.6% and 7.5% in the DNA only
group. Only one of three females from the ALVAC/Env group
was showed a positive response (2.8% CM9-specific CD8+ T
cells). This animal had the highest tetramer responses in all
the analyzed tissues and, therefore, was clearly different
from the other macaques included in the group. Finally, noTable 2 Comparison of cellular and humoral immune responses
Tissue Assay Imm
ALVA
(N =
PBMC Gag CM9 cellular responses a −
Vagina 1 of
Plasma Humoral responses b bAb c +++
Nab c ++
ADCC c +
ADCP c ++
Mucosa IgA 3 of
IgG 5 of
a Data from this report (Figs. 4A and 6D).
b Humoral immune response data are from Vargas-Inchaustegui et al
c Reflects relative magnitude.Gag CM9-specific T cells were found in any tissue for the
macaques vaccinated with the Pep/Env regimen. Taken
together (Table 1), the analysis of the Gag CM9-specific T
cells showed that the vaccine-induced cellular responses
were able to disseminate systemically, including genital
tract mucosa, which is a desirable feature for an effective
anti-HIV vaccine.3.5. Detection of early cellular responses in blood
The results obtained of CM9 tetramer responses for the
ALVAC/Env and RepAd/Env groups suggested that the time
of necropsy could have been suboptimal for the evaluation
of vaccine-induced cellular immunity in some vaccine
groups. Therefore, we also analyzed the peptide-induced
T cell responses for both Gag and Env in blood samples
collected earlier during the vaccination schedule. The time
point selected was two weeks after the 3rd vaccination
except for the RepAd/Env group, which was analyzed two
weeks after the 2nd immunizations. Comparison of the
responses for RepAd/Env, DNA&Env and DNA groups did not
show statistical differences between this time point (Fig. 7)
and after the 4th vaccination (Fig. 2). Because animals in the
Pep/Env group were found negative for both peptide and
CM9 tetramer responses performed in the necropsy samples,
they were excluded from this analysis.
Cellular immune responses were examined upon stimula-
tion of the PBMC with peptide pools covering Gag (Fig. 7A)
and the complete Env (Fig. 7D) followed by flow cytometry
and the responses were analyzed as described for Fig. 2. In
contrast to the results obtained in blood samples collected
at necropsy (Fig. 2), all four macaques in the RepAd/Env
group induced positive responses (IFN-γ, TNF-α production)
upon stimulation with both Gag and Env antigens (range of
0.04–0.07% and 0.04–0.13% of T cells for Gag) (Fig. 7A) and
Env (Fig. 7D), respectively. Interestingly, although negative
at the time of necropsy, five of the six macaques in the
ALVAC/Env group had peptide-induced responses at this
time point: three animals were positive for both Gag and
Env, while one animal each was positive for either of the two
antigens (ranges of 0.006% to 0.034% for Gag and 0.005%
to 0.018% for Env). As expected, all the macaques in the
two DNA groups were positive also at this time point. Theat necropsy.
une responses in different vaccine groups
C/Env
6)
RepAd/Env
(N = 4)
DNA&Env
(N = 4)
DNA
(N = 4)
+ +++ +++
3 N/A +++ +++
++ +++ ++
+++ +++ +
+++ ++ +
+++ ++ +
6 2 of 4 3 of 4 1 of 4
6 4 of 4 4 of 4 3 of 4
. [38].
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for the antigen-specific T cells of 0.04% to 0.85% (Gag) and of
0.23% to 2.1% (Env), and in the DNA only group of 0.08% to
0.85% (Gag) and 0.1% to 1.17% (Env). Comparison of these
four groups (Figs. 7A and B) showed significantly higher
levels of Gag- as well as Env-specific responses in the DNA
group compared to ALVAC/Env using ANOVA. Similarly,
analysis of total (Gag and Env) SIV-specific responses also
showed significant difference between the ALVAC/Env and
DNA group (p = 0.013) and DNA&Env group (p = 0.005). At
this time point, we did not find a significant difference
between RepAd/Env and DNA groups as we found at necropsy
(Fig. 2), although we noted a trend of the higher responses in
the groups that received DNA. We further observed that all
the macaques with measurable vaccine-induced cellular
responses elicited antigen-specific cytotoxic T lymphocytes
armed with Granzyme B (data not shown), indicating that
these cells are capable of killing SIV-infected cells.
Similar to the results obtained at necropsy (Fig. 2), the
antigen-specific responses against both Gag (Figs. 7B–C) and
Env (Figs. 7E–F) were mediated by CD4+ (Figs. 7B and E) and
CD8+ (Figs. 7C and F) T cells producing IFN-γ, TNF-α and both
cytokines. All vaccine regimens induced preferentially CD8+ T
cell responses with the exception of the Env responses in the
RepAd/Env group that showed a skewing of the responses
towards CD4+ T cells, similar to the data obtained at necropsy
(Fig. 2).
In summary, analysis of PBMC collected at earlier time
points during the vaccination schedule demonstrate that for
some vaccine regimens, especially ALVAC/Env and RepAd/
Env, the peak of cellular responses were elicited prior to
the final immunization. With regard to RepAd/Env, a similar
decline in cellular immune responses following Env immuni-
zation was seen in a recent study in which the Env boost
was administered in the same EM-005 adjuvant. The effect
was attributed to complex innate immune signaling arising
from persistent RepAd replication and the adjuvant in the
booster immunization, leading to a re-orientation of induced
adaptive responses (Thomas et al., submitted). An alternate
adjuvant pairing might be more appropriate for this vaccine
regimen.4. Discussion
In this report, we examined and compared the immune
responses induced by five different SIV vaccine regimens in
macaques to develop improved combinatorial vaccine strate-
gies aiming to improve the partially protective responses we
had previously reported. The main focus of this work was to
provide an analysis of the induced cellular immunity, while
the induced humoral immune responses have already been
reported elsewhere [38]. A summary of the key findings of the
induced cellular (this work) and humoral responses [38] found
at necropsy including binding antibody (bAb), neutralizing
antibody (Nab), antibody-dependent cell-mediated cytotox-
icity (ADCC) and antibody-dependent cell-mediated viral
inhibition (ADCVI) are presented in Table 2.
At necropsy, the highest frequency of Gag CM9-specific
T cells in PBMC were found in animals that receive vaccine
regimens including DNA and positive responses were also found
in all animals of the RepAd/Env group. The antigen-specificT cells induced by the DNA vaccine were preferentially
differentiated effector memory cells, while the RepAd/Env
induced more CM-like CD8+ T cells. Whether the different
phenotype of the Gag CM9-specific T cells will translate into
extended longevity or different effector function against
infected cells could not be addressed in this study since
immunogenicity of the different vaccines was analyzed
immediately after the last vaccination. However, we have
previously shown that DNA-based vaccines elicit potent
cytotoxic T cells and, importantly, we reported long-lasting
cellular immune responses, persisting for more the 5 years in
vaccinated macaques [32,33,73]. Similarly, persistent elite
control of viremia in macaques for more than 6.5 years
following SIVmac251 challenges was attributed in part to
cellular immunity elicited by RepAd/Env immunization [64].
We also compared SIV peptide-specific responses at a
selected time point during vaccination and at necropsy. The
DNA-based vaccines induced robust responses detectable at
both time points as expected since we previously showed
elicitation of high antigen-specific responses even after 2
vaccinations using the efficient intramuscular delivery follow-
ed by electroporation [27,28,30,32,33,73]. In contrast, we
noted a significant difference for the ALVAC/Env and the
RepAd/Env regimens with more responders and higher
responses at the earlier time point. As discussed above, this
may have involved a reorientation of immune responses in the
RepAd/Env group (Thomas et al., submitted). In any case,
depending on the vaccine regimen selection of optimal time
points for vaccine evaluation is critical to assess the potency
of the cellular immune responses. Importantly, all vaccines
(RepAd/Env, ALVAC/Env and DNA) were able to induce
cytotoxic T cell responses, an important characteristic to
evaluate the potency of the cellular immune response. In
addition, since we analyzed the Gag peptide and Gag CM9
tetramer responses at necropsy, this allowed us to directly
compare the results. In fact, we found that some of the
immunized macaques that failed to respond to Gag peptide
stimulation had indeed circulating Gag-specific cells in
peripheral blood (two animals from the RepAd/Env and one
from the ALVAC/Env group). It is possible that Gag-specific T
cells in these cases produce cytokines different than IFN-γ
and TNF-α measured in our assays. These data showed the
importance of employing both assays to get a comprehensive
evaluation of the vaccine-induced cellular immunity.
The presence of SIV-specific cellular responses at effector
sites, especially mucosal surfaces such as the genital tract, is
critical for the containment of the virus. Using live-attenuated
SIV as a vaccine model, others have demonstrated the potent
role of SIV-specific CD8+ T cells in the genital tract including
vagina and protection from vaginal SIV challenge [74,75].
Therefore, induction of immunity that readily disseminates
into these areas is a desirable feature of anti-HIV candidate
vaccines. We examined the dissemination of vaccine-induced
cell-mediated immunity into the genital tract using vaginal
samples taken at necropsy and observed that the highest
frequency of Gag CM9-specific T cells was consistently found
in the animals immunized with a vaccine regimens that
included DNA. Interestingly, we noted that the DNA vaccine
regimen administered by the IM route induced robust Gag
CM9-specific responses reaching up to 7% of the CD8+ T cells in
the vaginal samples. In contrast, the ALVAC/Env vaccine that
was also administered via the IM route showed only one of the
103Cellular immunity induced by different vaccine regimensthree females with Gag CM9-specific T cells in the genital
tract. Unfortunately, we could not assess these responses in
RepAd/Env group, which received the vaccine via mucosal
routes but did not have any female vaccinees. A few other
reports demonstrated the successful induction of cellular
responses in vaginal tissues of macaques using a vaccine
regimen consisting of DNAs, rMVA, and inactivated SIVmac239
particles administered via the oral route [76] or intraperito-
neal vaccination with a gp96-Ig chaperoning SIV antigens [77].
Of note, none of these vaccines were administered via the IM
route.
The analysis of the humoral responses at necropsy by
the different vaccine regimens revealed robust responses
in the plasma (binding and neutralizing antibodies) when
the vaccine included a protein component [38] (Table 2).
Similarly, DNA/Env, RepAd/Env and ALVAC/Env regimens
showed dissemination of SIV-specific IgG and IgA to mucosal
surfaces [38]. The DNA only vaccine regimen was clearly less
potent in eliciting SIV-specific mucosal IgG. The peptide/
MVA/Env regimen also had one of four animals with a strong
mucosal IgA response [38].
Thus, different vaccine platforms induce responses with
different characteristics. It is possible that the presence of
Env protein shifted the immune responses towards antibody
development at the expense of cellular immunity, since the
only vaccine regimen lacking a protein component (DNA
only) had the highest and more consistent cell-mediated
responses in the analyzed tissues. On the other hand the
RepAd/Env and ALVAC/Env showed good SIV-specific IgG and
IgA levels in rectal secretions, albeit RepAd/Env showed
relative low gag CM9 responses while ALVAC/Env did not
show detectable cellular responses at this time point. The
DNA&Env regimen, combining the robust cellular responses
associated with DNA and the higher antibody responses that
typically are induced by the protein component, induced the
more balanced immunity (Table 2). The immunity induced
by this regimen was characterized by high cellular responses
against Gag and Env and high levels of antibodies that were
shown to have several functional properties (neutralizing
activity, ADCC) [38]. The responses induced by the DNA&Env
protocol, both humoral and cellular, efficiently disseminated
into mucosal surfaces as demonstrated by the presence of
antigen-specific T cells in the genital tract and, similar to
animals vaccinated by the RepAd/Env protocol, the presence
of SIV-specific IgG and IgA in rectal secretions. Interestingly, in
addition to providing an excellent mucosal prime for antibody
responses, the RepAd/Env regimen induced cellular immunity
that had clearly distinct features: (i) the anti-Env cellular
responses were dominated by CD4+ T cells, and (ii) the Gag
CM9-specific CD8+ T cells induced by this regimen were
skewed towards a CMmemory phenotype, showing the highest
CM/EM ratio among all the vaccine regimens. Consistent with
these findings, the frequency of Gag CM9-specific CD8+ T cells
in the lymph nodes, a site where differentiated effector cells
are typically excluded, was higher in the RepAd/Env group.
Taken together, these results suggest that the RepAd
vaccine vector in combination with DNA or ALVAC including
Env protein represents promising combinatorial vaccination
strategies that may induce potent long-lasting cellular immu-
nity with early dissemination of both cellular and humoral
responses into mucosal sites. The efficacy of such combination
should be explored in the rhesus macaque model.5. Conclusion
We compared the cellular immune responses induced by five
vaccine regimens previously shown to confer protection in
macaques. We found potent dissemination of T cell responses
into secondary lymphoid tissues and effector anatomical sites,
including the genital tract, even when the vaccine regimen
was administered by the intramuscular route. Combination of
different presented vaccine regimens may induce a more
balanced, durable and protective immune responses.Acknowledgments
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